ArticleAbdominal radiology (New York)2026
Diagnosis of liver fibrosis degree in autoimmune liver disease by magnetic resonance diffusion-weighted imaging.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mortality trends and demographic-geographic disparities of autoimmune liver diseases among U.S. adults aged ≥45 years, 1999-2023.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibrosis is a key pathological feature of autoimmune liver diseases (AILD). This study evaluates the diagnostic potential of apparent diffusion coefficient (ADC) values from diffusion-weighted imaging (DWI) for liver fibrosis staging, liver damage, and inflammation in AILD patients.
methodsThis retrospective study analyzed the diagnostic performance of ADC values from DWI in 157 AILD patients. Liver biopsy served as the gold standard for fibrosis staging. The relationship between ADC values and liver function markers (AST, ALT) and inflammatory cytokines (IL-17, TNF-α) was assessed. To evaluate diagnostic accuracy, ADC values were compared across different fibrosis stages (S0 to S4) and inflammation grades (G0 to G4).
resultsADC values decreased progressively with increasing fibrosis stages and inflammation grades. Notably, ADC values were significantly lower in S4 compared to S0, with an AUC of 0.91. Pearson correlation analysis revealed significant negative correlations between ADC and serum IL-17 (r = -0.39, p < 0.001), TNF-α (r = -0.43, p < 0.001), as well as liver function markers, ALT (r = -0.49, p < 0.001) and AST (r = -0.46, p < 0.001). ROC analysis showed optimal ADC cut-off values for distinguishing fibrosis stages: 1.47 × 10
conclusionThis study highlights ADC values from DWI as a reliable non-invasive biomarker for assessing liver fibrosis and inflammation in AILD patients.
Indexed as
Identifiers
41204952What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.